CD123R(EQ)28zeta/EGFRt+ T cells
/ National Cancer Institute
- LARVOL DELTA
Home
Next
Prev
1 to 11
Of
11
Go to page
1
August 27, 2026
NCI-2014-01147: Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
(clinicaltrials.gov)
- P1 | N=31 | Active, not recruiting | Sponsor: City of Hope Medical Center | Trial completion date: Aug 2026 ➔ Jul 2027 | Trial primary completion date: Aug 2026 ➔ Jul 2027
Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • T Acute Lymphoblastic Leukemia • CD123 • FLT3 • IL3RA
September 17, 2025
NCI-2014-01147: Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
(clinicaltrials.gov)
- P1 | N=31 | Active, not recruiting | Sponsor: City of Hope Medical Center | Trial completion date: Aug 2025 ➔ Aug 2026 | Trial primary completion date: Aug 2025 ➔ Aug 2026
Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • T Acute Lymphoblastic Leukemia • CD123 • FLT3 • IL3RA
June 17, 2025
NCI-2014-01147: Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
(clinicaltrials.gov)
- P1 | N=31 | Active, not recruiting | Sponsor: City of Hope Medical Center | Trial primary completion date: May 2025 ➔ Aug 2025
Trial primary completion date • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • T Acute Lymphoblastic Leukemia • CD123 • FLT3 • IL3RA
January 04, 2025
NCI-2014-01147: Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
(clinicaltrials.gov)
- P1 | N=31 | Active, not recruiting | Sponsor: City of Hope Medical Center | Trial completion date: Dec 2024 ➔ Jun 2025 | Trial primary completion date: Dec 2024 ➔ May 2025
Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • T Acute Lymphoblastic Leukemia • CD123 • FLT3 • IL3RA
February 16, 2024
Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
(clinicaltrials.gov)
- P1 | N=31 | Active, not recruiting | Sponsor: City of Hope Medical Center | Trial completion date: Dec 2023 ➔ Dec 2024 | Trial primary completion date: Dec 2023 ➔ Dec 2024
Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • T Acute Lymphoblastic Leukemia • CD123 • FLT3 • IL3RA
September 11, 2023
Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
(clinicaltrials.gov)
- P1 | N=31 | Active, not recruiting | Sponsor: City of Hope Medical Center | Trial completion date: Jun 2023 ➔ Dec 2023 | Trial primary completion date: Jun 2023 ➔ Dec 2023
Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • T Acute Lymphoblastic Leukemia • CD123 • FLT3 • IL3RA
January 05, 2023
Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
(clinicaltrials.gov)
- P1 | N=31 | Active, not recruiting | Sponsor: City of Hope Medical Center | Trial completion date: Dec 2022 ➔ Jun 2023 | Trial primary completion date: Dec 2022 ➔ Jun 2023
Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Hematological Malignancies • Immune Modulation • Inflammation • Leukemia • Myelodysplastic Syndrome • Oncology • T Acute Lymphoblastic Leukemia • CD123 • FLT3
February 21, 2022
Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
(clinicaltrials.gov)
- P1 | N=31 | Active, not recruiting | Sponsor: City of Hope Medical Center | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2021 ➔ Dec 2022 | Trial primary completion date: Dec 2021 ➔ Dec 2022
Enrollment closed • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Hematological Malignancies • Immune Modulation • Inflammation • Leukemia • Myelodysplastic Syndrome • Oncology • T Acute Lymphoblastic Leukemia • CD123 • FLT3
December 17, 2020
Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
(clinicaltrials.gov)
- P1; N=42; Recruiting; Sponsor: City of Hope Medical Center; Trial completion date: Nov 2020 ➔ Nov 2021; Trial primary completion date: Nov 2020 ➔ Nov 2021
Clinical • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Hematological Malignancies • Immune Modulation • Inflammation • Leukemia • Myelodysplastic Syndrome • Oncology • T Acute Lymphoblastic Leukemia • CD123 • FLT3 • PCR
January 23, 2020
Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
(clinicaltrials.gov)
- P1; N=42; Recruiting; Sponsor: City of Hope Medical Center; Trial completion date: Dec 2019 ➔ Nov 2020; Trial primary completion date: Dec 2019 ➔ Nov 2020
Clinical • Trial completion date • Trial primary completion date • CD123 • FLT3 • PCR
March 12, 2019
Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
(clinicaltrials.gov)
- P1; N=42; Recruiting; Sponsor: City of Hope Medical Center; N=60 ➔ 42
Clinical • Enrollment change
1 to 11
Of
11
Go to page
1